Skip to main content

JPM Global Healthcare Fund

JPM Global Healthcare Fund is an equity fund managed by JPM in the Sektor – Helse category. Actively managed global healthcare fund from J.P.

About this fund

Categorised as Sektor – Helse, JPM Global Healthcare Fund is an equity fund from JPM.

Launched in 2009, it has 17 years behind it.

Measured on return so far this year measured in NOK as of 13.11.2026, the fund is number 9 of 18 in its category.

Tracking error against its benchmark is 4.9%.

It is run by a team of 2.

The manager states a volatility of 14.0% for the fund.

Manager
JPM
Category
Sektor – Helse
Region
Global
Sector
Health Care
Style
Sector Focus
SFDR
Article 8
ISIN
LU0432979614
Inception
2009-10-02
Benchmark
MSCI World Healthcare Index (Total Return Net)
AUM
3.6 bn USD
Returns
YTD 9.1% · 1Y 11.9% · 3Y 7.2% · 5Y 5.9%

Portfolio managers

Actively managedEquityGlobalHealth care
YTD Return · NOK
+9,1 %from NAV
Calculated NOK return from USD · A (acc) - USD (NOK Calculated)
Last NAV 612,25 USD · 16 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+9,1 %
YTD
+11,9 %
1y
+7,2 %
3y, annualised
+5,9 %
5y, annualised
+10,4 %
10y, annualised
Fund size
3,6 mrd. USD
Total fund AUM
Management fee
1,50 %
Annual · class A Akk.
Ongoing charge
1,80 %
Annual · class A Akk.
Performance fee
None
Stated by the manager
Annual cost on platforms
1,12 %–1,24 %
Class A Akk. · 4 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
Oct 2009
ISIN LU0432979614
BenchmarkMSCI World Health Care
Fund website
Risk
Volatility (stated by the manager)14,0 %
Sharpe Ratio0,22
Beta1,01
Info Ratio−0,36
Tracking Error4,9 %
About the fund
The fund

JPM Global Healthcare Fund is an actively managed global healthcare fund with history going back to 2009. Its management company, J.P. Morgan Asset Management, is the asset management business of the listed financial group JPMorgan Chase & Co. The mandate covers pharmaceuticals, biotechnology, healthcare services, medical technology and life sciences.

Investment philosophy

The fund has a lasting tilt towards the largest companies by market capitalisation, with stable core positions in large, established companies.

The managers

Dominic Valder and Bartjan van Hulten share responsibility and are both healthcare specialists based in London. Valder has managed the fund since October 2022. He joined J.P. Morgan in 2020 from Fidelity International, where he was a senior analyst for the US healthcare sector, and has a background in pharmaceutical research and a degree in biochemistry from Oxford. He also manages the JDOC ETF. Van Hulten has been a healthcare analyst in J.P. Morgan's US equity research since 2018 and became co-manager in 2024. He previously founded the healthcare fund Medex Capital.

The portfolio

The portfolio has a lasting emphasis on pharmaceuticals and biotechnology, with North America as the largest region. Johnson & Johnson, Eli Lilly and AbbVie are examples of steady top holdings.

FundTelligence description · 18/10/2026
Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

Portfolio managers

BA
Portfolio Manager
On the fund since Feb 25, 2024
DO
Portfolio Manager
On the fund since Oct 26, 2022

Position in the peer group

Sector Health Care Equities · 31 funds in the peer group. The number ranked and the date are stated per period. 12 of them converted to NOK.

7 of 18 funds ranked on a calculated return

#9/ 18Year to date
+9.09% NOK
From NAV as of 16 Nov 2026

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

13 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#12/ 221 year
+11.90% NOK
From NAV as of 16 Nov 2026

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#12/ 223 years (ann.)
+7.23% NOK
From NAV as of 16 Nov 2026

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

#15/ 225 years (ann.)
+5.91% NOK
From NAV as of 16 Nov 2026

as of 13 Nov 2026 · Converted from USD to NOK

About the figures

9 of 31 funds in the group hold no figure for the date and are not counted. 1 funds with older figures: up to 5 business days.

Comparison basis

Year to date

Comparison basis: Ranked among 18 of 31 funds · 13 left out (5 share class outside the rule, 3 missing return, 1 return as of an earlier date, 1 history too short, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

1 year

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

3 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

5 years (ann.)

Comparison basis: Ranked among 22 of 31 funds · 9 left out (4 missing return, 2 return as of an earlier date, 3 return without a stated date) · returns as of 12 Nov 2026–13 Nov 2026

The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data